A new and simple blood test has been found to efficiently and accurately detect the presence of aggressive prostate cancer, according to research by Queen Mary University of London.
In combination with the current prostate specific antigen (PSA) test, the new test could help men avoid unnecessary and invasive biopsies, over-diagnosis and over-treatment.
Prostate cancer is the most common cancer in Western men, with 1.3 million new cases being diagnosed each year worldwide. It is currently detected using a blood test that measures PSA levels. Although it provides early diagnosis, the PSA blood test has a low specificity (high false positives) with about 75 per cent of all PSA positive results ending up with negative biopsies that do not find cancer.
When a high PSA level in the blood is detected, the patient undergoes a tissue biopsy of the prostate gland, which is invasive and carries a significant risk of bleeding and infection. On biopsy, the majority of patients with elevated PSA levels are found not to have cancer.
Additionally, most diagnosed early-stage prostate cancers are not fatal if left untreated. The current practice of the combined PSA test and biopsy for prostate cancer therefore results in unnecessary biopsies and over-diagnosis and overtreatment of many men.
Circulating tumor cells
The new prostate cancer test (the Parsortix® system from ANGLE plc) detects early cancer cells, or circulating tumor cells (CTCs), that have left the original tumour and entered the bloodstream prior to spreading around the body. By measuring intact living cancer cells in the patient’s blood, rather than the PSA protein which may be present in the blood for reasons other than cancer, it potentially provides a more accurate test for prostate cancer.
The study, published in the Journal of Urology, looked at the use of the CTC test in 98 pre-biopsy patients and 155 newly diagnosed prostate cancer patients enrolled at St Bartholomew’s Hospital in London.
The research team found that the presence of CTCs in pre-biopsy blood samples were indicative of the presence of aggressive prostate cancer, and efficiently and non-invasively predicted the later outcome of biopsy results.
When the CTC tests were used in combination with the current PSA test, it was able to predict the presence of aggressive prostate cancer in subsequent biopsies with over 90 per cent accuracy, better than any previously reported biomarkers.
Additionally, the number and type of CTCs present in the blood was also indicative of the aggressiveness of the cancer. Focusing on more aggressive prostate cancer may reduce over-treatment and unnecessary biopsies for benign and non-aggressive conditions.
‘A paradigm shift in the way we diagnose prostate cancer’
Lead researcher Professor Yong-Jie Lu from Queen Mary’s Barts Cancer Institute said: “The current prostate cancer test often leads to unnecessary invasive biopsies and over-diagnosis and overtreatment of many men, causing significant harm to patients and a waste of valuable healthcare resources. There is clearly a need for better selection of patients to undergo the biopsy procedure.
“Testing for circulating tumour cells is efficient, non-invasive and potentially accurate, and we’ve now demonstrated its potential to improve the current standard of care. By combining the new CTC analysis with the current PSA test, we were able to detect prostate cancer with the highest level of accuracy ever seen in any biomarker test, which could spare many patients unnecessary biopsies. This could lead to a paradigm shift in the way we diagnose prostate cancer.”
As this is a single centre study, the results need to be further validated in other independent research centres before the CTC test is available either privately or on the NHS in the UK, which could take a further 3-5 years. Clearance by the US Food and Drug Administration could also take 3-5 years.
The Latest on: Prostate cancer
via Google News
The Latest on: Prostate cancer
- Telix Pharmaceuticals and GE Healthcare: Maximising 68Ga Supply for Prostate Cancer Imagingon October 13, 2019 at 4:00 pm
Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian ...
- Mushrooms as prostate cancer fighters, laziness gene, money and happiness, calorie counting, mass shootings and social stigmaon October 13, 2019 at 4:00 pm
If you love mushrooms, good news. A new study has found that making mushrooms a staple in your diet may help prevent prostate cancer. The study, authored by a Japanese Ph.D. candidate, followed nearly ...
- Eating mushrooms can reduce men's risk of prostate cancer, study revealson October 13, 2019 at 2:40 am
Fresh champignon mushrooms in a basket on wooden table. [Standard] It’s a love or hate ingredient, but a new study has revealed a link between eating mushrooms and lower risk of prostate cancer.
- Men Have Fun in Prostate Cancer Trialon October 11, 2019 at 10:09 am
you might hear it...we become kind of like boys again, you know? And you think you can conquer the world!" — Patrick, 73 years old Men with prostate cancer just want to have fun — and play ...
- Prostate Cancer Treatment Industry – Treatment, Outlook, Analysis, Research, Review to 2023on October 11, 2019 at 4:34 am
The Prostate Cancer Treatment industry has also suffered a certain impact, but still maintained a relatively optimistic growth, the past four years, Prostate Cancer Treatment market size to maintain ...
- Prostate Cancer: One Food That Could Spare You From The Deadly Diseaseon October 11, 2019 at 3:50 am
One thing that men do not want to ever experience is having prostate cancer. This is a debilitating disease, with cases increasing every year. While many men get anxious about contracting this deadly ...
- ESSA Pharma: Promising Novel Therapy For Treatment Of Prostate Canceron October 10, 2019 at 5:37 pm
ESSA recently presented promising new data on its next-generation EPI-7386 N-terminal domain androgen receptor inhibitor at ESMO for the treatment of prostate cancer. Plans to file IND and begin ...
- Men who conceive with assisted reproduction at increased prostate cancer riskon October 10, 2019 at 11:40 am
(Reuters Health) - Men who conceive children using assisted reproduction techniques (ART) like in vitro fertilization (IVF) are more likely to develop prostate cancer and may benefit from screening, a ...
- Penny Lancaster in tears recalling Rod Stewart's battle against 'aggressive' prostate canceron October 10, 2019 at 8:01 am
Penny Lancaster found herself in tears on Loose Women today when she opened up about husband Rod Stewart’s prostate cancer. While performing at an event in aid of prostate cancer last month, the ...
- Gene-based therapy helps fight advanced prostate canceron October 10, 2019 at 6:00 am
A drug that targets faulty gene repair may buy more time for some men with advanced prostate cancer, a recent clinical trial found. Experts called the study "landmark," because it zeroed in on men ...
via Bing News